Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

MBI vs PMI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MBI Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 5–4 Matrix Metrics)

MBI Overall Winner 6-Pillar Tally: MBI 5 – 1 PMI Matrix Metrics: MBI 5 – 4 PMI

As of Nov 19, 2026, MBIA Inc. (MBI) is the stronger overall head-to-head candidate over Picard Medical, Inc. (PMI) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MBI carries a Unified Composite Score of 44.0/100 (HOLD) at $4.37 (87.0x Forward P/E, 22.8% operating margin), whereas PMI carries 48.4/100 (HOLD) at $6.30 (N/M Forward P/E, -248.1% operating margin).

  • Composite vs. Pillar Nuance: While PMI currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. MBI 44.0/100 HOLD), MBI captures the overall institutional head-to-head verdict (5–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (22.8% vs. -248.1% operating margin) and revenue trajectory (+46.7% vs. +38.6% YoY).
  • Technical & Structure Timing Caution: MBI is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 40.8); meanwhile PMI trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 42.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MBI vs PMI
MBI NYSE Head-to-Head Winner
MBIA Inc.
Surety Insurance
$4.37
-2.24% 1D
Market Cap $228.1M
TTM Revenue $101M
Forward P/E 87.0x
Beta / 30D Vol 0.25β · 31% Vol
Unified Composite Score
44.0 / 100 HOLD
Tech 46.0 Fund 52.0 Flow 58.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -2.5%) with fading momentum, RSI 41
RSI-14: 40.8 · SMA20: $4.55 · SMA50: $4.49
PMI NYSE American
Picard Medical, Inc.
Surgical & Medical Instruments & Apparatus
$6.30
-2.17% 1D
Market Cap $17.1M
TTM Revenue $6.3M
Forward P/E N/M
Beta / 30D Vol 54.06β · 134% Vol
Unified Composite Score
48.4 / 100 HOLD
Tech 39.0 Fund 45.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 42
RSI-14: 42.1 · SMA20: $7.55 · SMA50: $7.62

6-Pillar Scorecard Institutional Category Breakdown (MBI 5 – 1 PMI)

Columns: Metric · MBI · PMI
1. Valuation Multiples MBI
Forward P/E 87.0x N/M
Trailing P/E 87.0x 2.9x
PEG Ratio 1.71x N/M
EV / Revenue 2.3x 3.2x
2. Growth & Scale MBI
Revenue Growth (YoY) +46.7% +38.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $101M $6.3M
Market Cap $228.1M $17.1M
3. Profitability & Quality MBI
Gross Margin 88.1% 18.6%
Operating Margin 22.8% -248.1%
Net Profit Margin -159.4% 0.0%
Return on Equity (ROE) 0.0% 0.0%
4. Balance Sheet & Cash Flow MBI
Cash Generation (TTM) -$120M -$17M
Cash Flow Margin -118.8% N/A
Net Cash / Leverage 0.0% ROE $3.2M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PMI
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 46.5% (10th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Distribution NEUTRAL · Neutral
6. R&D & Supply-Chain Moat MBI
OpEx & R&D Intensity 65.3% of Rev ($66M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Insurance - Specialty Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MBI (5) vs PMI (4)
Institutional Metric MBI PMI Criterion Row Edge
Market Capitalization
Scale
$228.1M $17.1M Larger Scale MBI
Trailing P/E Ratio
Valuation
87.0x 2.9x Lower Multiple PMI
Forward P/E Ratio
Valuation
87.0x N/M Lower Multiple MBI
Revenue Growth (YoY)
Growth
+46.7% +38.6% Higher Growth MBI
Operating Margin (TTM)
Profitability
22.8% -248.1% Higher Margin MBI
Net Profit Margin
Profitability
-159.4% 0.0% Higher Margin PMI
Return on Equity (ROE)
Capital Efficiency
0.0% 0.0% Higher ROE Tie
52-Week Range Position
Momentum
5% ($4–$8) 34% ($0–$18) Stronger Trend PMI
Beta / 30D Volatility
Risk Regime
0.25β · 31% Vol 54.06β · 134% Vol Lower Realized Risk MBI
Unified Institutional Score
Composite Signal
44.0 / 100 (HOLD) 48.4 / 100 (HOLD) Higher Composite PMI
Trailing 12M Revenue (USD)
Operating Scale
$101M $6.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
88.1% 18.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.71x PEG · 2.3x EV/Rev N/M PEG · 3.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$120M (0.0% ROE) -$17M ($3.2M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MBI +33.67 pp
MBI: -0.91% · PMI: -34.58%
3M Horizon PMI +107.08 pp
MBI: -10.82% · PMI: +96.26%
6M Horizon PMI +3468.62 pp
MBI: -29.29% · PMI: +3439.33%
1Y Horizon PMI +190.83 pp
MBI: -42.8% · PMI: +148.03%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period MBI Revenue PMI Revenue MBI Op. Margin PMI Op. Margin Margin Leader
FY2018 $160M N/A -182.7% N/A MBI
FY2019 $280M N/A -128.2% N/A MBI
FY2020 $280M N/A -205.0% N/A MBI
FY2021 $190M N/A -235.4% N/A MBI
FY2022 $150M N/A -126.6% N/A MBI
FY2023 $10M N/A 6814.3% N/A MBI
FY2024 $40M $0M 1035.7% -312.3% MBI
FY2025 $80M $0M -221.2% -268.4% MBI

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MBI BREAKDOWN
98d in phase · OBV NEUTRAL
Current IV 46.5%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MBI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PMI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PMI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MBI Moat Profile Scale & Operating Efficiency Moat
Insurance - Specialty Operator
Competes within the Insurance - Specialty value chain with $228.1M market capitalization and 22.8% operating margin.
OpEx & R&D Reinvestment 65.3% of Rev ($66M)
90D Engineering Disclosures 0 Published
PMI Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $17.1M market capitalization and -248.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MBI vs PMI Key Questions & Quantitative Answers

As of Nov 19, 2026, MBIA Inc. (MBI) is the stronger overall head-to-head candidate over Picard Medical, Inc. (PMI) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MBI carries a Unified Composite Score of 44.0/100 (HOLD) at $4.37 (87.0x Forward P/E, 22.8% operating margin), whereas PMI carries 48.4/100 (HOLD) at $6.30 (N/M Forward P/E, -248.1% operating margin). Composite vs. Pillar Nuance: While PMI currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. MBI 44.0/100 HOLD), MBI captures the overall institutional head-to-head verdict (5–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (22.8% vs. -248.1% operating margin) and revenue trajectory (+46.7% vs. +38.6% YoY). Technical & Structure Timing Caution: MBI is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 40.8); meanwhile PMI trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 42.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MBI leads the Growth & Scale pillar: MBI posts +46.7% YoY revenue growth and +0.0% YoY earnings growth on $101M TTM revenue (88.1% gross margin, 22.8% operating margin), compared with PMI at +38.6% YoY revenue growth and +0.0% YoY earnings growth on $6.3M TTM revenue (18.6% gross margin, -248.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), MBI cumulative revenue shifted -50.0% while PMI shifted N/A. In operating R&D and SG&A reinvestment, MBI deploys 65.3% of Rev ($66M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PMI.

MBI screens cheaper on headline valuation multiples. MBI trades at 87.0x Forward P/E, 87.0x Trailing P/E, 1.71x PEG, and 2.3x EV/Revenue (-118.8% FCF margin), whereas PMI trades at N/M Forward P/E, 2.9x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MBI (0.0% ROE) versus PMI (0.0% ROE) capital efficiency.

In options market volatility and institutional positioning, MBI carries 46.5% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.25β · 31% Vol realized risk). By comparison, PMI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (54.06β · 134% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.